We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Okyo Pharma Limited | OKYO | London | Ordinary Share |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
91.00 | 91.00 |
Industry Sector |
---|
MINING |
Top Posts |
---|
Posted at 04/4/2023 07:08 by babbler Not a surprise. UK investors don't get OKYO. |
Posted at 14/3/2023 12:21 by faraweigh2 Management and investors well placed now for future gains.Funding in place for significant growth. |
Posted at 01/9/2022 15:13 by faraweigh2 Long and strong over on NASDAQ.Investors understand the prospect over there.Volumes increasing and with an upward trajectory too. |
Posted at 13/12/2021 11:44 by kasspass It seems this company lacks credibility and lost investors interest . Sp not moving on what appears to be a positive rns. Volume says all. |
Posted at 18/9/2020 09:10 by dodobird25 Volsung. You are evidently a committed OKYO investor. I also believe that the company has growth potential, and I intend to hold, through thick and thin, until the share price approaches double the current value, whenever that happens. Only then will I consider my position. My current holding is 200,000 shares @ approx. 11.1p ave.I have researched the company as fully as I am able, but from my experiences of other companies, I realise that there are investors out there with more detailed informatio than I am able to access. Should you have any information or insights, that you are willing to share, I would appreciate your input. Regards, and best wishes with your investments. |
Posted at 17/9/2020 09:46 by dodobird25 Why are you referring to OKYO investors as losers? I gather that building up a holding following extensive research and in anticipation of future mid- or long-term profits is not your preferred trading methodology?I have taken the opportunity of topping up earlier today, although my two 30,000 purchases @10.37p and 10.34p respectively are displayed as sells. You are welcome to your opinion, but I have every reason to suppose that there are long-term profits to look forward to. Meanwhile, I await the company's report at the AGM on Sept 25. Regards. |
Posted at 06/8/2020 14:06 by spurs90 Jim Mellon has just dumped his entire stake in tiddler Okyo Pharma, which is developing therapies for inflammatory eye diseases and chronic pain management. Below is a link to the announcement that shows he went down from owning just over 4pc to almost 0.Now, that does seem a strange move by Mellon - a 'billionaire' investor that is said to be friends with Brexit leader Aaron Banks - given Okyo shares have been surging in recent weeks to almost 17p. Watching... |
Posted at 28/7/2020 09:06 by spurs90 OKYO Pharma Limited("OKYO" or the "Company") Issue of convertible loan notes to raise £3,500,000 OKYO, the life sciences and biotechnology company, focused on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain, is pleased to announce that it has raised £3,500,000 through the issue of convertible loan notes ("CLNs"). The proceeds of the CLNs will be used for working capital purposes as detailed below. The CLNs carry an interest rate of 2.15% compounding and have maximum term of 4 years. The CLNs convert into ordinary shares at a price of 8.5p per share. Conversion will be subject to shareholder approval and no conversions may take place prior to 28 February 2021. The CLNs were placed with a small number of private investors. OKYO intends to use the net proceeds received from the CLNs, to further the development of its clinical pipeline. The person who arranged for the release of this announcement on behalf of the Company was Keeren Shah, Chief Financial Officer of OKYO. |
Posted at 28/3/2019 21:28 by newtothisgame3 !FOLLOWFEED!YOUTUBEVThe price I expect in #OKYO will sound like a Ramp at these current levels but Im hoping for 5p eventually. It may seem a tall order but I think it will be reached when we get positive news. … … … … Standard listing Okyo joined the standard list section of the London Market in July after a reverse takeover into former miner West African Mining. The majority shareholder is the Parmetta Group, which holds the original IP for Chemerin. Picking winners among small biotechs can be difficult for professionals, let alone amateur investors, but the previous successes and track record of management suggest if the compounds are commercial, they will know how to move them forward. At 2.25p, Okyo is valued at £12mln and is much smaller currently than Tiziana (£139mln) but you would not bet against it following a similar path. 14 March 2019 OKYO releases preclinical data on OKYO-0101 at the 14th Congress on Ocular Pharmacology and Therapeutics, 2019 demonstrating its potential to treat dry eye. 07 March 2019 Presentation of Preclinical Data Demonstrating Potential of OKYO-0101 for Dry Eye Treatment |
Posted at 01/8/2018 12:41 by zen12 See rns they have £2m in the bank. Also large investors with significant holdings. So what you’re saying is totally incorrect. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions